Zometa Study in Pediatric Acute Lymphoblastic Leukemia

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for one fourth of all childhood cancers & 74 % of childhood leukemia. Based upon drug registry data, children prescribed more than three courses of systemic glucocorticoids yearly faced a 20% increase in age-adjusted fracture rates. Rapid recovery occurred once glucocorticoids were discontinued, and fracture rates returned to expected for age by 1 year after treatment (Journal Of Clinical Endocrinology & Metabolism 2009). The investigators will study the role of bisphosphonates in the prevention of secondary osteoporosis in children & adolescents treated for ALL in the Children's Cancer Hospital -Egypt.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Cancer Hospital Egypt 57357
• Treatments: Calcium; Calcium, Dietary; Diphosphonates; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Age above 5 & below 18 years at the time of diagnosis.

• Newly diagnosed ALL patients.

• Not previously treated, previous steroid intake not more than 72 hours.

• Treated according to St Judy study XV protocol.

Exclusion Criteria:

• Previous steroid intake more than 72 hours.

• Less than 5 years